City of Hope, an
innovative biomedical research, treatment and educational institution with over
6,000 employees, is dedicated to the prevention and cure of cancer and other
life-threatening diseases and guided by a compassionate, patient-centered
Founded in 1913 and
headquartered in Duarte, California, City of Hope is a remarkable non-profit
institution, where compassion and advanced care go hand-in-hand with excellence
in clinical and scientific research. City of Hope is a National Cancer
Institute designated Comprehensive Cancer Center and a founding member of the
National Comprehensive Cancer Network, an alliance of the nation’s leading
cancer centers that develops and institutes standards of care for cancer
We are seeking a
talented and motivated Postdoctoral Fellow to become a part of the
multidisciplinary research team headed by Dr. Ajay Goel, who recently relocated
to the City of Hope. His research is highly focused on understanding the
interplay between genetic and epigenetic alterations in colorectal, pancreatic,
gastric and esophageal cancers. One of the primary translational research goals
is to develop novel diagnostic, prognostic, and predictive biomarkers for
various gastrointestinal cancers, as well as study immune regulation and
identify novel therapeutic targets (e.g. targeted therapies, immune checkpoint
inhibitors) for various GI malignancies. Our multidisciplinary research group
comprises of basic biologists, gastroenterologists, surgeons, oncologists and
bioinformaticians, undertaking a number of collaborative projects involving
large international consortia.
Exploration of cell-free and
circulating DNA-based, liquid biopsy biomarkers for the early-detection of
gastrointestinal cancers (including colorectal, pancreatic, gastric, liver
methodologies involving non-coding RNAs-based biomarkers for the earlier
diagnosis, prognosis and predictive responses to chemotherapy in gastrointestinal
Study the role of aberrant DNA
methylation, histone modifications and non-coding RNAs (miRNA, lncRNAs,
snoRNAs, piRNAs etc.) in various GI malignancies.
Understanding the genetic basis
of early-onset and familial/hereditary colorectal cancers
Molecular mechanisms of cancer
pathogenesis, the role of stem cells in the context of chemo resistance
chemo-sensitization in cancer cells.
The role of tumor
microenvironment, immune regulation and identification of various targeted
therapies (e.g. immune checkpoint inhibitors) in GI cancers.
The role of exosomes as
biological determinants, and exosomal cargo as disease biomarkers
Gut microbiome and its
influence in gastrointestinal cancers
experience and skills required for consideration:
PhD and/or MD/PhD.
Evidence of first author
Prior molecular, cancer biology
and/or translational research experience and evidence of project
experience and skills:
Relevant experience in cancer
genetics and epigenetics.
Prior hands-on experience in
developing cell-free DNA and RNA-based, liquid biopsy assays
Preference will be given to
individuals who had previous experience with microarray and
next generation sequencing-based platforms (MiSeq, HiSeq, NovaSeq,
RRBS, ChIP-Seq, MeDip etc.).
Strong background in
biochemistry and/or molecular biology, as well as experience
in identification and development of therapeutic targets in
high-throughput target screens etc.).
Desire to grow and develop
skills in order to become an independent Investigator.
Possess excellent communication
and writing skills.
Enthusiastic and highly
Able to think creatively and
Possess good organizational
Able to work independently and
in a team environment.
Curriculum Vitae and
coordinates of three scientific mentors.
A cover letter highlighting
your research interests, a brief statement explaining how your past
research ties in with the goals of our laboratory, and future career
City of Hope is committed
to creating a diverse environment and is proud to be an equal
opportunity employer. All qualified applicants will receive
consideration for employment without regard to race, religion, color,
national origin, sex, sexual orientation, gender identity, age, status as
a protected veteran, or status as a qualified individual with disability.